Nimbus Biotechnologie, the trusted supplier of ADME-Tox products
and services, has announced that it has changed its name to Sovicell
GmbH, effective immediately. At the same time the Company has launched
a new website at www.sovicell.com. The name change reflects the
Company´s move to become a full range, international supplier of
ADME-Tox products and services for pre-clinical research. It is also a
reflection of the growth in the business in the last year under a new
more internationally focused management team.
Commenting on the name change Dr Hinnerk Boriss, CEO said:
"This name change supports our Company´s commercial development
and more accurately reflects our new positioning. We are continually
enhancing our ADME-Tox product portfolio and services to meet our
pharmaceutical and biotechnology customers´ needs and look forward to
continuing to work with our supportive existing partners as well as
expanding our client base internationally."
Since its foundation in 1994, Sovicell (formerly Nimbus) has
successfully developed and commercialised its proprietary TRANSIL(R)
bead-based in vitro testing procedures for reliably measuring a drug
candidate´s membrane permeability and protein binding. Such testing
can enable early and accurate prediction of the efficacy and safety of
drug candidates and prevent costly failures in clinical trials. Last
year the Company began enhancing the portfolio and now provides
cryopreserved hepatocytes exclusively for Cytonet.
In addition, since 2007 Sovicell (formerly Nimbus) has been
offering a blood-to-brain adsorption kit which is based on natural
biological membranes and is valuable in the development of CNS drugs.
This is the only product of its kind available on the market. Further
new products are to follow shortly.
To further facilitate the continued expansion of Sovicell´s
business, the Company recently moved to new state-of-the-art premises
in Leipzig´s BioCity: Deutscher Platz 5b, 04103 Leipzig Germany.
About Sovicell:
Sovicell, which changed its name from Nimbus Biotechnologie in
February 2008, is dedicated to providing trusted state-of-the-art
ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology)
products and services that enable its customers to rapidly obtain
accurate and reproducible pharmacokinetic data about their drug
candidates or other test substances.
The TRANSIL technology platform, which is a novel bead based
system, underpins the Company´s reliable membrane permeability and
protein binding assays. While SOVICYTE cell lines, with their in
vivo-relevant metabolic properties, form the core of Sovicell´s drug
metabolism and cytotoxicity assays. Sovicell has proved a trustworthy
partner to the pharmaceutical and biotechnology industries over the
past ten years. Located in Leipzig, Germany, the company employs 14
people and is co-financed by several renowned Venture Capital firms.
TRANSIL(R) and SOVICYTE(R) are registered trademarks of Sovicell
GmbH.
Further information can be found at: www.sovicell.com
Notes for editors:
About TRANSIL:
Sovicell´s patented TRANSIL technology derives its name from
transition silica and refers to proprietary surface modified porous
silica beads which serve as a carrier material for biological
molecules or structures such proteins, enzymes and membranes. The
beads have applications in protein binding assays (TRANSIL Albumin
binding kits or TRANSIL AGP Binding kits) and membrane permeability
assays (TRANSIL Intestinal Absorption kit or TRANSIL blood-brain
Absorption kit). The TRANSIL products offer customer´s a number of
advantages:
-- Rapid - 2 minute incubation
-- Ready to use format
-- Easy to use
-- Highly reproducible
-- Accurately mimics in vivo physiology
-- Suitable for high throughput
